Navigation Links
Monogram Announces 2008 Second Quarter Financial Results
Date:7/29/2008

collaborators at ASCO in June of a study demonstrating the superiority of HERmark over FISH as a predictor of trastuzumab response ("Total HER2 and HER2 Homodimer Levels Predict Response to trastuzumab").

-- Commercial introduction in July of HERmark for assessment of HER2 status in patients with breast cancer -- providing a precise and quantitative measurement of HER2 total protein and HER2 homodimer levels by a CLIA-validated assay through Monogram's CAP-certified clinical laboratory.

-- Establishment of initial sales organization to introduce HERmark to the oncology community.

-- Introduction at ASCO of a Collaborative Biomarker Study, designed to (i) compare conventional IHC and FISH methods of HER2 testing with the quantitative measurements of HER2 total protein and HER2 homodimers provided by HERmark, and (ii) to describe the expression/co-expression profiles identified by Monogram's HER1 and HER3 Total Protein Assays along with HER2 total protein and homodimer levels identified by HERmark to facilitate analyses of how such measurements may correlate with certain laboratory and clinical parameters, including disease progression.

"Current technologies -- IHC, FISH and CISH -- are well recognized by breast cancer researchers and oncologists as being inadequate for the accurate assessment of HER2 status," continued Young. "This is the important clinical need that HERmark addresses by providing accurate and quantitative measurements of the drug target."

Physicians currently use these semi-quantitative technologies to determine HER2 status and decide whether or not to prescribe Herceptin(R). Inaccurate measurements of HER2 may lead to inappropriate therapy selection. Guidance recently issued jointly by ASCO and CAP (the College of American Pathologists) indicated that approximately 20% of HER2 determinations conducted in local laboratories by current testing technologies may be inaccurate.

"We have correlated the HERmark as
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Monogram Announces First Medicare Payment for Trofile(TM)
2. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
3. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
4. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
5. Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 CarePoint Health is proud ... our network, CarePoint Health Medical Group. Our system ... Hundreds of highly skilled and experienced physicians comprise ... top doctors and practices in Hudson County, representing ... represents CarePoint Health’s commitment to provide the highest ...
(Date:7/29/2014)... July 29, 2014 Many people complain about ... they do each morning is put on glasses to see ... These same individuals also may be dissatisfied with their vision ... , Cataracts may cause difficulty driving, especially at night due ... or find one’s golf ball, see the TV, sew or ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Tylenol ... individuals who allegedly suffered serious liver injuries due ... move forward in a multidistrict litigation underway in ... Liebhard LLP reports. According to an Order dated ... deadlines pertaining to bellwether case and discovery issues. ...
(Date:7/29/2014)... 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. , The study finds that the ...
(Date:7/29/2014)... Historically, Memorial Day kicks off a ... celebrated throughout that time by picnics, barbecues and beach ... mark the start of a period that will witness ... In 2012 nearly 1.000 people were killed in crashes ... to Labor Day. , The summer's warmer weather, longer ...
Breaking Medicine News(10 mins):Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), a leading ... venous reflux disease, today,announced the appointment of Peter Osborne ... Administration., Mr. Osborne joins VNUS with over 25 ... Osborne had served as the Company,s,Interim CFO since October ...
... 3 times weekly may increase risk, study suggests , , ... a Mediterranean diet rich in fish, fresh fruits and vegetables, ... their children against asthma and allergies, new research suggests. , ... included 468 mother and child pairs that were followed from ...
... Matters of the mind can affect matters of the heart. ... researchers has found that major anxiety and/or depression, can double ... This is one of the first studies to focus on ... were hospitalized for events such as a heart attack. , ...
... be saved , , FRIDAY, Jan. 18 (HealthDay News) -- If ... die from sudden cardiac arrest could be dramatically reduced. , ... calling for renewed efforts to teach CPR and to find ... the lifesaving technique. , "There is a tremendous opportunity for ...
... Jan. 18 LifeSync Corporation is,pleased to announce ... of Operations. Ms. McLane comes to LifeSync Corporation ... Johnson Company, where she,most recently held the position ... joining Cordis, Ms. McLane spent over 13,years at ...
... brain tumors, dual implantation of radioactive seeds and ... a study led by specialists at the Neuroscience ... University Hospital. , The study, published in the ... that patients treated with simultaneous implantation of radioactive ...
Cached Medicine News:Health News:VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer 2Health News:Mediterranean Diet for Mom Fends Off Asthma, Allergies in Kids 2Health News:Depression and anxiety can double chances of heart ailments 2Health News:Heart Association Renews Call for CPR Training 2Health News:Heart Association Renews Call for CPR Training 3Health News:LifeSync Corporation Appoints Nancy McLane as Senior Vice President Operations 2Health News:Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors 2
(Date:7/29/2014)... 2014  Sequenom, Inc. (NASDAQ: SQNM ), ... today reported total revenues of $39.8 million for the ... to revenues of $24.5 million for the second quarter ... which was sold on May 30, 2014, has been ... results have been excluded from continuing operations for all ...
(Date:7/29/2014)... 29, 2014 Regado Biosciences, Inc. (Nasdaq: ... Phase 3 clinical development of Revolixys™ Kit (previously known ... today announced that it will hold a conference call ... at 8:30 a.m. EDT to discuss its second quarter ... participants and investors may access the conference call by ...
(Date:7/29/2014)... Pfenex Inc. (NYSE MKT: PFNX) today announced that ... 8,333,333 shares of its common  stock at a price to ... stock was offered by Pfenex. In addition, Pfenex has granted ... additional shares of common stock at the initial public offering ... NYSE MKT under the symbol "PFNX." William ...
Breaking Medicine Technology:Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Pfenex Announces Closing of Initial Public Offering 2
... Ill. , March 14 NorthShore University HealthSystem (NorthShore) ... the American College of Cardiology annual scientific sessions from the EVEREST ... novel, first-in-class catheter-based device,  is a safe and effective alternative to ... ...
... March 12 HEI, Inc. (Pink Sheets: HEII) ... has achieved qualification to MIL-P-50884E.  This qualification was awarded ... Agency.  DSCC manages Military qualifications for the electronics industry. ... Tempe, Arizona to manufacture rigid-flex and flex ...
Cached Medicine Technology:Minimally Invasive Heart Valve Therapy Improves Heart Function, Quality of Life for Mitral Regurgitation Patients 2Minimally Invasive Heart Valve Therapy Improves Heart Function, Quality of Life for Mitral Regurgitation Patients 3Minimally Invasive Heart Valve Therapy Improves Heart Function, Quality of Life for Mitral Regurgitation Patients 4HEI, Inc. Announces Qualification to MIL-P-50884E 2
... enclosures are designed for ... other process gas to ... HEPA filtration, heating/cooling, humidification, ... also available, along with ...
... removes chemical fumes, allowing safe ... charcoal filters remove most organic ... exhaust flow speed = 100 ... Includes air speed monitor, quick-release ...
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... These corrosion proof polypropylene exhaust hoods are ... of tanks and draw a stream of ... away from the operator. Other sizes and ... lateral, and double-slot are available on special ...
Medicine Products: